ANAB - ANAPTYSBIO, INC

66.11
-0.480   -0.726%

Share volume: 739,550
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$66.59
-0.48
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
60%
Profitability 46%
Dept financing 41%
Liquidity 50%
Performance 80%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
12.28%
1 Month
19.35%
3 Months
38.16%
6 Months
83.03%
1 Year
212.13%
2 Year
210.38%
Key data
Stock price
$66.11
P/E Ratio 
N/A
DAY RANGE
$65.06 - $71.67
EPS 
-$0.46
52 WEEK RANGE
$17.11 - $73.30
52 WEEK CHANGE
$197.52
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
28.748 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$853,434
AVERAGE 30 VOLUME 
$711,486
Company detail
CEO: Daniel R. Faga
Region: US
Website: anaptysbio.com
Employees: 100
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AnaptysBio, Inc. engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.

Recent news